HM15421/GC1134A could become the first subcutaneous enzyme replacement therapy for Fabry disease, with BioMarin paying $70 million upfront.
|Articles|January 10, 2020
CPhI and AAPS Partner to Expand Scientific Content
Author(s)BioPharm International Editors
The companies will kick off their partnership with CPhI North America, a conference that hosts the North American pharmaceutical supply chain.
Advertisement
CPhI and the American Association of Pharmaceutical Scientists (AAPS) announced on Jan.10, 2020 that they are entering into a partnership to expand the scientific content of activities sponsored by CPhI, including CPhI North America, a conference that hosts the North American pharmaceutical supply chain.
“Partnering is a cornerstone of our strategy, enabling CPhI to offer our participants knowledge and insights from experts spanning the pharmaceutical industry supply chain,” said Anthony Pombal, CPhI North America show director, in a company press release. “We could not find a more appropriate partner than AAPS, which matches the professional breadth of our audiences with scientific expertise covering every facet of the discovery, development, production, and regulation of pharmaceutical products. We look forward to a productive and mutually beneficial relationship.”
“Our community of members has scientific expertise across the entire continuum of the pharmaceutical enterprise,” added Joseph Polli, PhD, AAPS president, in the press release. “Partnering with CPhI to make our broad knowledge base available to their diverse pharmaceutical audiences reflects our long-standing commitment to advancing global health through research, education, and innovation.”
CPhI North America will take place from May 5–7, 2020 at the Pennsylvania Convention Center in Philadelphia, PA.
Source:
Advertisement
Related to this article
DAX-044 aims to confine IL-12 activity to tumors and avoid the toxicity that has limited IL-12 therapy, with phase 1 testing expected in 2027.
Boehringer Ingelheim will pay Sino Biopharmaceutical $358 million upfront and near-term for options on six biologic oncology programs, deepening a partnership that began in 2024.
Teva will commercialize etanercept-ykro (Eticovo) and infliximab-abda, adding 2 TNF inhibitor biosimilars to US options for inflammatory diseases.
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
Advertisement
Advertisement
Trending on BioPharm International
1
Policy Leaders Urge Treasury to Narrow Biotech Outbound Investment Rule
2
Shilpa CDMO Commits $50 Million to Scale Peptide Capacity in India
3
Spyre’s Anti-TL1A Antibody SPY072 Misses in Psoriatic Arthritis and Axial Spondyloarthritis, Shifts Focus to Hidradenitis Suppurativa
4
Boehringer Ingelheim Licenses Six Preclinical ADC and T-Cell Engager Programs From SBP Group in Deal Worth Up to $7 Billion
5